

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SMITHKLINE BEECHAM CORPORATION	02/16/2007
RECEIVING PARTY DATA	
Name:	GLAXO GROUP LIMITED
Street Address:	Glaxo Wellcome House
Internal Address:	Berkeley Avenue
City:	Greenford, Middlesex
State/Country:	UNITED KINGDOM
Postal Code:	UB6 ONN
PROPERTY NUMBERS Total: 6	
Property Type	Number
Patent Number:	6951861
Patent Number:	6642240
Application Number:	10958744
Patent Number:	7071196
Application Number:	10838838
Application Number:	11334267
CORRESPONDENCE DATA	
Fax Number:	(919)483-7977
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	919 483 2370
Email:	julie.d.mcfalls@gsk.com
Correspondent Name:	GlaxoSmithKline
Address Line 1:	Five Moore Drive, P.O. Box 13398
Address Line 2:	MAIB475
Address Line 4:	Research Triangle Pa, NORTH CAROLINA 27709-3398

CH \$240.00 6951861

500225526

PATENT
REEL: 018898 FRAME: 0671

ATTORNEY DOCKET NUMBER:	PI3806US
NAME OF SUBMITTER:	Charles E. Dadswell
Total Attachments: 3 source=PI3806#page1.tif source=PI3806#page2.tif source=PI3806#page3.tif	

PI3806US
Docket Number

Assignment

WHEREAS, **SMITHKLINE BEECHAM CORPORATION**, a corporation organized and existing under and by virtue of the laws of the State of Pennsylvania and having its principal place of business at One Franklin Plaza, PO Box 7929, Philadelphia, Pennsylvania 19101, USA, owns an invention entitled **CHEMICAL COMPOUNDS** (hereinafter called "the invention") for which patent application No. **9923748.9** was filed on **October 7, 1999** in the **United Kingdom** and for which an international patent application **PCT/EP00/09722** was filed **October 5, 2000** designating the United States of America; and for which US National Phase application no. **10/089,964** was filed in the **United States Patents and Trademark Office** on **May 8, 2002**, and granted as **US Patent 6,951,861** on **October 4, 2005**; and for which Continuation patent application number **10/190,170** was filed in the **United States Patents and Trademark Office** on **July 3, 2002** and granted as **US Patent No. 6,642,240** on **November 4, 2003**; and for which Reissue patent application number **10/958,744** was filed in the **United States Patents and Trademark Office** on **October 5, 2004**; and for which Continuation patent application number **10/637,825** was filed in the **United States Patent and Trademark Office** on **August 8, 2003** and granted as **US Patent No. 7,071,196** on **July 4, 2006**; and for which Continuation patent application number **10/838,838** was filed in the **United States Patent and Trademark Office** on **May 4, 2004**, and was **Abandoned**; and for which continuation patent application number **11/334,267** was filed in the **United States Patent and Trademark Office** on **January 18, 2006**; and

WHEREAS, **GLAXO GROUP LIMITED**, a company organized and existing under and by virtue of the laws of England and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN England, is desirous of acquiring the whole right, title and interest in and to said invention and improvements and said application, and in and to any Letters Patent to be obtained therefor, in the United States, its territories and possessions; and

NOW, THEREFORE, to all whom it may concern, be it known that **SMITHKLINE BEECHAM CORPORATION**, for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and

PI3806US
Docket Number

transfer my/our whole right, title and interest in and to said invention and improvements to said **GLAXO GROUP LIMITED**, throughout the United States of America, its territories and possessions, and in and to said application and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America;

AND, I/we do hereby authorize and request the issue of any Letters Patent in the respective areas referred to said **GLAXO GROUP LIMITED** as assignees of my/our whole right, title and interest in and to the same for the sole use and behalf of the said assignees, their successors and assigns as their interests appear herein;

AND, I/we warrant that I/we have not knowingly conveyed to others any right in said invention, improvements, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing said invention and improvements and that I/we have good right to assign the same to **GLAXO GROUP LIMITED**;

AND, I/we the undersigned **SMITHKLINE BEECHAM CORPORATION**, for the consideration aforesaid, do hereby agree that I/we or my/our executors or legal representatives, will provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, application papers, affidavits, assignments and other documents which may be necessary or desirable to more effectually secure to and vest in said **GLAXO GROUP LIMITED**, their successors and assigns, the whole right, title and interest in and to the said invention and improvements, applications, Letters Patent, rights, title and interest hereby sold, assigned and conveyed, or intended so to be. *This assignment should be deemed effective as of October 7, 1999.*

IN WITNESS whereof, Charles E. DADSWELL as Attorney of each of **GLAXO GROUP LIMITED** and **SMITHKLINE BEECHAM CORPORATION** by virtue of Powers of Attorney granted by **GLAXO GROUP LIMITED** and **SMITHKLINE BEECHAM CORPORATION** respectively has hereunto set his respective hand.

PI3806US
Docket Number

SIGNED by the said CHARLES E. DADSWELL as the Attorney of each of GLAXO GROUP LIMITED
and SMITHKLINE BEECHAM CORPORATION:



Charles E. DADSWELL

Date: February 16, 2007